The thienotriazolodiazepine Ro 11-1464 increases plasma apoA-I and promotes reverse cholesterol transport in human apoA-I transgenic mice

British Journal of Pharmacology

Volumn 164, Issue 6, 2011, Pages 1642-1651

  Zanotti, I ^a   Maugeais, C ^b   Pedrelli, M ^a,e   Gomaraschi, M ^c   Salgam, P ^b   Calabresi, L ^c   Bernini, F ^a   Kempen, H ^d  

^a UNIVERSITY OF PARMA   (Italy)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c UNIVERSITY OF MILAN   (Italy)

^d Dybly AG   (Switzerland)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

apolipoprotein A I; HDL; hepatocyte; macrophage; reverse cholesterol transport; thienotriazolodiazepine

Indexed keywords

9 METHYL 4 PHENYL 6H THIENO[3,2 F][1,2,4]TRIAZOLO[4,3 A][1,4]DIAZEPINE; APOLIPOPROTEIN A1; DIAZEPINE DERIVATIVE; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; RO 11 1464; THIENOTRIAZOLODIAZEPINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG ACTIVITY; DRUG DOSE INCREASE; DRUG EFFICACY; ENZYME ACTIVITY; GENE EXPRESSION; IN VITRO STUDY; IN VIVO STUDY; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; LIVER WEIGHT; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE CHOLESTEROL TRANSPORT; TRANSGENIC MOUSE; UPREGULATION;

ALANINE TRANSAMINASE; ALKALINE PHOSPHATASE; ANIMALS; APOLIPOPROTEIN A-I; ATHEROSCLEROSIS; AZEPINES; CHOLESTEROL; FECES; GENE EXPRESSION REGULATION; HEPATOCYTES; HUMANS; LIPID METABOLISM; LIPIDS; LIVER; MACROPHAGES; MALE; MICE; MICE, TRANSGENIC; ORGAN SIZE; PHOSPHATIDYLCHOLINE-STEROL O-ACYLTRANSFERASE; THIOPHENES;

EID: 80055006316     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01376.x     Document Type: Article

References (42)

1. Adorni MP, Zimetti F, Billheimer JT, Wang N, Rader DJ, Phillips MC, et al,. (2007). The roles of different pathways in the release of cholesterol from macrophages. J Lipid Res 48: 2453-2462. (Pubitemid 350058756)
2. Badimon JJ, Badimon L, Fuster V, (1990). Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J Clin Invest 85: 1234-1241. (Pubitemid 20123768)
3. Berard AM, Foger B, Remaley A, Shamburek R, Vaisman BL, Talley G, et al,. (1997). High plasma HDL concentrations associated with enhanced atherosclerosis in transgenic mice overexpressing lecithin-cholesteryl acyltransferase. Nat Med 3: 744-749. (Pubitemid 27298717)
4. Berthou L, Duverger N, Emmanuel F, Langouet S, Auwerx J, Guillouzo A, et al,. (1996). Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice. J Clin Invest 97: 2408-2416. (Pubitemid 26187327)
5. Bortnick AE, Rothblat GH, Stoudt G, Hoppe KL, Royer LJ, McNeish J, et al,. (2000). The correlation of ATP-binding cassette 1 mRNA levels with cholesterol efflux from various cell lines. J Biol Chem 275: 28634-28640.
6. Calabresi L, Villa B, Canavesi M, Sirtori CR, James RW, Bernini F, et al,. (2004). An omega-3 polyunsaturated fatty acid concentrate increases plasma high-density lipoprotein 2 cholesterol and paraoxonase levels in patients with familial combined hyperlipidemia. Metabolism 53: 153-158. (Pubitemid 38168885)
7. Calabresi L, Pisciotta L, Costantin A, Frigerio I, Eberini I, Alessandrini P, et al,. (2005). The molecular basis of lecithin: cholesterol acyltransferase deficiency syndromes: a comprehensive study of molecular and biochemical findings in 13 unrelated Italian families. Arterioscler Thromb Vasc Biol 25: 1972-1978. (Pubitemid 41243471)
8. Calabresi L, Favari E, Moleri E, Adorni MP, Pedrelli M, Costa S, et al,. (2009). Functional LCAT is not required for macrophage cholesterol efflux to human serum. Atherosclerosis 204: 141-146.
9. Cuchel M, Rader DJ, (2006). Macrophage reverse cholesterol transport: key to the regression of atherosclerosis? Circulation 113: 2548-2555. (Pubitemid 43948034)
10. Duffy D, Rader DJ, (2006). Emerging therapies targeting high-density lipoprotein metabolism and reverse cholesterol transport. Circulation 113: 1140-1150.
11. Duverger N, Kruth H, Emmanuel F, Caillaud JM, Viglietta C, Castro G, et al,. (1996). Inhibition of atherosclerosis development in cholesterol-fed human apolipoprotein A-I-transgenic rabbits. Circulation 94: 713-717. (Pubitemid 26289227)
12. Favari E, Zanotti I, Zimetti F, Ronda N, Bernini F, Rothblat GH, (2004). Probucol inhibits ABCA1-mediated cellular lipid efflux. Arterioscler Thromb Vasc Biol 24: 2345-2350. (Pubitemid 39658040)
13. Folch J, Lees M, Sloane Stanley GH, (1957). A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 226: 497-509.
14. Frikke-Schmidt R, Nordestgaard BG, Jensen GB, Tybjaerg-Hansen A, (2004). Genetic variation in ABC transporter A1 contributes to HDL cholesterol in the general population. J Clin Invest 114: 1343-1353. (Pubitemid 40385306)
15. Furbee JW, Jr, Sawyer JK, Parks JS, (2002). Lecithin: cholesterol acyltransferase deficiency increases atherosclerosis in the low density lipoprotein receptor and apolipoprotein E knockout mice. J Biol Chem 277: 3511-3519. (Pubitemid 34953221)
16. Hellerbach J, Zeller P, Binder D, Hromatka O, (1977). Thienotriazolodiazepines. US Patent 4,155,193.
17. Iverson SJ, Lang SL, Cooper MH, (2001). Comparison of the Bligh and Dyer and Folch methods for total lipid determination in a broad range of marine tissue. Lipids 36: 1283-1287. (Pubitemid 34007983)
18. Jian B, de la Llera-Moya M, Ji Y, Wang N, Phillips MC, Swaney JB, et al,. (1998). Scavenger receptor class B type I as a mediator of cellular cholesterol efflux to lipoproteins and phospholipid acceptors. J Biol Chem 273: 5599-5606. (Pubitemid 28124029)
19. Joyce CW, Wagner EM, Basso F, Amar MJ, Freeman LA, Shamburek RD, et al,. (2006). ABCA1 overexpression in the liver of LDLr-KO mice leads to accumulation of pro-atherogenic lipoproteins and enhanced atherosclerosis. J Biol Chem 281: 33053-33065. (Pubitemid 46036688)
20. Kempen HJ, (1997a). A thienotriazolobenzodiazepine (Ro11-1464) increases production of apolipoprotein A-I by Hep-G2 cells, and elevates its plasma concentration in the hamster. Circulation 96 (Suppl.): 484-485.
21. Kempen HJ, (1997b). Use of a thienotriazolodiazepine to increase apolipoprotein A-I levels. PCT Publication WO97/09048, US Patent 5,854,23.
22. Kozarsky KF, Donahee MH, Rigotti A, Iqbal SN, Edelman ER, Krieger M, (1997). Overexpression of the HDL receptor SR-BI alters plasma HDL and bile cholesterol levels. Nature 387: 414-417. (Pubitemid 27227207)
23. Lewis GF, Rader DJ, (2005). New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res 96: 1221-1232. (Pubitemid 40962099)
24. Lie J, Lankhuizen IM, Gross B, van Gent T, van Haperen R, Scheek L, et al,. (2005). Fenofibrate reverses the decline in HDL cholesterol in mice overexpressing human phospholipid transfer protein. Biochim Biophys Acta 1738: 48-53. (Pubitemid 43122129)
25. de la Llera-Moya M, Rothblat GH, Connelly MA, Kellner-Weibel G, Sakr SW, Phillips MC, et al,. (1999). Scavenger receptor BI (SR-BI) mediates free cholesterol flux independently of HDL tethering to the cell surface. J Lipid Res 40: 575-580. (Pubitemid 29116161)
26. Luttringer O, Theil FP, Lave T, Wernli-Kuratli K, Guentert TW, de Saizieu A, (2002). Influence of isolation procedure, extracellular matrix and dexamethasone on the regulation of membrane transporters gene expression in rat hepatocytes. Biochem Pharmacol 64: 1637-1650. (Pubitemid 35339377)
27. Mulya A, Lee JY, Gebre AK, Thomas MJ, Colvin PL, Parks JS, (2007). Minimal lipidation of pre-beta HDL by ABCA1 results in reduced ability to interact with ABCA1. Arterioscler Thromb Vasc Biol 27: 1828-1836. (Pubitemid 47207180)
28. Nieland TJ, Penman M, Dori L, Krieger M, Kirchhausen T, (2002). Discovery of chemical inhibitors of the selective transfer of lipids mediated by the HDL receptor SR-BI. Proc Natl Acad Sci U S A 99: 15422-15427. (Pubitemid 35403950)
29. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, et al,. (2003). Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 290: 2292-2300. (Pubitemid 37430562)
30. Oram JF, (2003). HDL apolipoproteins and ABCA1: partners in the removal of excess cellular cholesterol. Arterioscler Thromb Vasc Biol 23: 720-727. (Pubitemid 36566158)
31. Plump AS, Scott CJ, Breslow JL, (1994). Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci U S A 91: 9607-9611. (Pubitemid 24297964)
32. Princen J, Kooistra T, (1998). Method for controlling the level of plasma lipoproteins for treating Alzheimer's Disease. European Patent Office Bulletin. EP875′247.
33. Rader DJ, Alexander ET, Weibel GL, Billheimer J, Rothblat GH, (2009). The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. J Lipid Res 50 (Suppl.): S189-S194.
34. Rubin EM, Krauss RM, Spangler EA, Verstuyft JG, Clift SM, (1991). Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature 353: 265-267. (Pubitemid 21896769)
35. Rye KA, Clay MA, Barter PJ, (1999). Remodelling of high density lipoproteins by plasma factors. Atherosclerosis 145: 227-238. (Pubitemid 29359129)
36. Tall AR, (2008). Cholesterol efflux pathways and other potential mechanisms involved in the athero-protective effect of high density lipoproteins. J Intern Med 263: 256-273. (Pubitemid 351207349)
37. Tangirala RK, Tsukamoto K, Chun SH, Usher D, Pure E, Rader DJ, (1999). Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice. Circulation 100: 1816-1822. (Pubitemid 29498389)
38. Tanigawa H, Billheimer JT, Tohyama J, Fuki IV, Ng DS, Rothblat GH, et al,. (2009). Lecithin: cholesterol acyltransferase expression has minimal effects on macrophage reverse cholesterol transport in vivo. Circulation 120: 160-169.
39. Trigatti B, Rayburn H, Vinals M, Braun A, Miettinen H, Penman M, et al,. (1999). Influence of the high density lipoprotein receptor SR-BI on reproductive and cardiovascular pathophysiology. Proc Natl Acad Sci U S A 96: 9322-9327. (Pubitemid 29374753)
40. Yancey PG, Bortnick AE, Kellner-Weibel G, Llera-Moya M, Phillips MC, Rothblat GH, (2003). Importance of different pathways of cellular cholesterol efflux. Arterioscler Thromb Vasc Biol 23: 712-719. (Pubitemid 36566157)
41. Zanotti I, Poti F, Pedrelli M, Favari E, Moleri E, Franceschini G, et al,. (2008). The LXR agonist T0901317 promotes the reverse cholesterol transport from macrophages by increasing plasma efflux potential. J Lipid Res 49: 954-960.
42. Zhang Y, Zanotti I, Reilly MP, Glick JM, Rothblat GH, Rader DJ, (2003). Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo. Circulation 108: 661-663. (Pubitemid 36999247)